Pulmonary Hypertension: Classification and Pathogenesis
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Hypertension II: Pathophysiology
您也可能阅读
通过共同作者、期刊和引用图与本文相关的文章。
Gongli Pang1, Xiaoxia Wang2, Ru Zhao1
1Department of Cardiology, Shanxi Cardiovascular Hospital, Taiyuan, Shanxi, China.
甲状腺功能低下症与肺动脉高血压 (PAH) 的风险增加有关. 这项研究使用门德尔随机化来调查甲状腺功能障碍和PAH之间的关联,没有发现反向因果关系.
10:20Right Ventricular Systolic Pressure Measurements in Combination with Harvest of Lung and Immune Tissue Samples in Mice
Published on: January 16, 2013
07:11Establishment and Validation of a Rat Model of Pulmonary Arterial Hypertension Associated with Pulmonary Fibrosis
Published on: May 23, 2025
科学领域:
背景情况:
研究的目的:
主要方法:
主要成果:
结论: